Optimizing LDL-C: Individualizing Treatment Using Statins and Nonstatin Therapy
Tracking # 20-860390
Course overview
Optimizing LDL-C: Individualizing Treatment Using Statins and Nonstatin Therapy will review how to use the risk assessment tool, the 2018 LDL-C guidelines recommendations including the role of the non-statin agents ezetimibe and PCSK9 inhibitors. Expert faculty will discuss the role of bempedoic acid, an agent recently approved for LDL-C management, as well as results from trials of inclisiran, an agent in late-stage development.
Subject areas
This course counts toward the state boards and subject areas below.
Louisiana State Board of Medical Examiners - Physicians & Surgeons
Physician & Surgeon
State Medical Board of Ohio
Doctor of Medicine
Doctor of Osteopathic Medicine
Disclosure statements
The Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.
Program Faculty
The faculty, authors and content developers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Rachel M. Bond, MD, FACC: Nothing to disclose
Ty J. Gluckman, MD, FACC, FAHA: Nothing to disclose
Planners and Managers
The planners and mangers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Terry Ann Glauser, MD, MPH: Nothing to disclose
Content Reviewers
The content reviewers reported the following relevant financial relationships that they or their spouse/partner have with commercial interests:
Katie Propst, PhD: Nothing to disclose
FDA DISCLOSURE
The contents of some CME activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.